ACTRN12605000077662招募中3 期
A non-randomised Phase III study to evaluate the effectiveness of Deflazacort in boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.
The Children's Hospital at Westmead0 个研究点目标入组 20 人开始时间: 2005年8月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 4 Years 至 15 Years（—）
- 性别
- All
入选标准
- •Duchenne muscular dystrophy, walking independently, failed Prednisone.
排除标准
- •No exclusion criteria
研究者
相似试验
进行中（未招募）
1 期
Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+Patient with Diffuse Large B cells with IPI=0 not previously treatedMedDRA version: 18.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017279-77-BEYSARC650
进行中（未招募）
1 期
Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+Patient with Diffuse Large B cells with IPI=0 not previously treatedMedDRA version: 12.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2009-017279-77-FRGELARC420
已完成
2 期
A Randomised Phase II/III Trial of Weekly Cisplatin Chemoradiotherapy +/- low-dose celecoxib for locoregional nasopharyngeal carcinomaACTRN12608000449336Shiraz University of Medical Sciences50
已完成
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in elderly patients with previously untreated systemic peripheral T-cell lymphomasT-cell lymphoma10025321NL-OMON41578niversity Medicine Goettingen25
尚未招募
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomasT cell lymphoma10025321NL-OMON31642ordic Lymphoma Group40